Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abdullah Sakin

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
Journal of Cancer Research and Therapeutics|December 13, 2022
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology groupCihan Erol, Mehmet Ali Nahit Sendur, Irem Bilgetekin, et al.
Head & Neck|April 21, 2023
Major and minor salivary gland cancers: A multicenter retrospective studyMuhammet Bekir Hacioglu, Bulent Erdogan, Murat Bardakcı, et al.
Medicina (Kaunas, Lithuania)|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World AnalysisMustafa Seyyar, Pervin Can Şancı, Abdullah Sakin, et al.
The Oncologist|September 7, 2023
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology GroupÇağlar Ünal, Abdulmunir Azizy, Senem Karabulut, et al.
Cancers|June 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group StudyBahadır Köylü, Özde Melisa Celayir, Harun Muğlu, et al.
International Journal of Cancer|October 28, 2025
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology GroupSalih Tunbekici, Gokhan Sahin, Sercan Ön, et al.
BMC Cancer|February 11, 2023
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyCengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
Journal of Cancer Research and Therapeutics|December 13, 2022
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology groupCihan Erol, Mehmet Ali Nahit Sendur, Irem Bilgetekin, et al.
Head & Neck|April 21, 2023
Major and minor salivary gland cancers: A multicenter retrospective studyMuhammet Bekir Hacioglu, Bulent Erdogan, Murat Bardakcı, et al.
Medicina (Kaunas, Lithuania)|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World AnalysisMustafa Seyyar, Pervin Can Şancı, Abdullah Sakin, et al.
The Oncologist|September 7, 2023
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology GroupÇağlar Ünal, Abdulmunir Azizy, Senem Karabulut, et al.
Cancers|June 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group StudyBahadır Köylü, Özde Melisa Celayir, Harun Muğlu, et al.
International Journal of Cancer|October 28, 2025
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology GroupSalih Tunbekici, Gokhan Sahin, Sercan Ön, et al.
BMC Cancer|February 11, 2023
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyCengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, et al.
Pageof 10